Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Address
1700 OWENS STREET, SUITE 205
SAN FRANCISCO, CA 94158
Founded
2009
Number of Employees
284
Website
http://www.nurixtx.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | - | - | - | - | - | $15 | $15 |
| Average Price | - | - | - | - | - | - | - | - | - | - | $9.57 | $9.57 |
| # Shares Purchased | - | - | - | - | - | - | - | - | - | - | 1,548 | 1,548 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | - | - | 150.8% | 150.8% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | - | - | 7.4% | 7.4% |
| Excess Total Return | - | - | - | - | - | - | - | - | - | - | 143.4% | 143.4% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | - | - | 99% | 90% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at NRIX make a trade.
Creating a free account takes less than one minute